Merck & Co., Inc. (NYSE:MRK) is Tealwood Asset Management Inc.’s 5th Largest Position

Tealwood Asset Management Inc. lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,012 shares of the company’s stock after selling 1,201 shares during the period. Merck & Co., Inc. comprises 1.8% of Tealwood Asset Management Inc.’s investment portfolio, making the stock its 5th biggest position. Tealwood Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $4,445,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in MRK. LFA Lugano Financial Advisors SA boosted its holdings in Merck & Co., Inc. by 250.0% in the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after purchasing an additional 225 shares during the last quarter. JJJ Advisors Inc. acquired a new position in Merck & Co., Inc. in the 2nd quarter valued at about $27,000. PRW Wealth Management LLC acquired a new position in Merck & Co., Inc. in the 4th quarter valued at about $41,000. Aspire Private Capital LLC acquired a new position in Merck & Co., Inc. in the 4th quarter valued at about $55,000. Finally, Thor Advisors LLC acquired a new position in Merck & Co., Inc. in the 1st quarter valued at about $69,000. 76.05% of the stock is owned by institutional investors and hedge funds.

MRK has been the topic of several recent analyst reports. BMO Capital Markets boosted their target price on shares of Merck & Co., Inc. from $83.00 to $84.00 and gave the company a “market perform” rating in a report on Wednesday, May 1st. Mizuho reiterated a “buy” rating and issued a $97.00 target price on shares of Merck & Co., Inc. in a report on Monday, August 5th. Credit Suisse Group reiterated a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, June 21st. Finally, Leerink Swann initiated coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $92.56.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the sale, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the sale, the chief financial officer now owns 354,378 shares in the company, valued at $30,274,512.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by corporate insiders.

Shares of MRK stock traded down $0.32 during trading hours on Thursday, hitting $86.59. The company had a trading volume of 1,930,464 shares, compared to its average volume of 9,479,614. The company’s fifty day moving average is $83.55 and its 200 day moving average is $81.12. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. Merck & Co., Inc. has a fifty-two week low of $66.10 and a fifty-two week high of $87.25. The stock has a market capitalization of $222.50 billion, a PE ratio of 19.95, a price-to-earnings-growth ratio of 1.75 and a beta of 0.56.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm had revenue of $11.76 billion for the quarter, compared to analyst estimates of $10.94 billion. During the same period in the prior year, the business posted $1.06 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities analysts forecast that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.54%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What is the definition of market timing?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.